2025-06-24
1. Summary of the Week
From June 14 to 20, a total of 13 biotech agreements were announced globally. Within the China biotech industry, there were 7 notable deals, comprising 2 out-licensing agreements, 2 in-licensing deal, and 3 domestic transactions.
The leading out-licensing deal of the week was signed between Simcere and NextCure, involving the phase I asset, SIM0505 with a total deal value of $745 million. The top domestic deal of the week is between Protein Innovation and Science Sun for the pre-clinical stage asset, NeoAB33, with a total deal value of $2.78 million and an upfront payment of $1.39 million.
On the global front, 6 agreements were signed during the same period. The most significant deal was between ProcessaPharmaceuticals and Intact Therapeutics for the Phase II asset, YH12852. This deal includes an upfront payment of $2.5 million, with a total potential value of $455 million.
2025年6月14日-20日，全球医药市场共签署了13项资产授权和合作协议。中国市场共达成7项交易，包括2项出海交易、2项引进交易和3项国内交易。
本周值得关注的出海交易是先声药业就临床一期ADC资产SIM0505与NextCure达成合作，总金额可达7.45亿美元。国内交易方面，赛升药业引进参股公司华大蛋白的临床前资产NeoAB33，首付款139万美元，总金额可达278万美元。
国际市场上，本周共签署了6项资产授权和合作协议。值得关注的一项交易是ProcessaPharmaceuticals授予Intact Therapeutics临床二期资产YH12852独家许可权，首付款250万美元，总金额可达4.55亿美元。
2. Licensing Deals
2a. China Section
2b. Global Section
3. M&A Deals
4. Top Deals of 2025
5. 2019-2024 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一
ACCESS CHINA
Event Name:
2025-06-15 ACCESS CHINA BD Forum @BIO, Virtual & Boston
BioToChina.org 